PT-141 (Bremelanotide)

FDA Approved

Melanocortin Receptor Agonist | Sexual Dysfunction Treatment

Half-life: ~2.7 hours
4 studies
2021 latest
2 recent
FDA Approved
Dose Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance
Frequency As needed before sexual activity; max 1 dose per 24 hours
Cycle Use as needed for sexual enhancement
Storage Refrigerate at 2-8°C, use reconstituted solution within 30 days
Accumulation Plotter

Community Research

Join others researching PT-141 — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

FDA-approved melanocortin receptor agonist for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Works centrally in the nervous system to trigger sexual arousal pathways independent of vascular mechanisms, unlike traditional ED medications.

Mechanism of Action

Selectively activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of peripheral vascular mechanisms. Works within 45 minutes with effects lasting 6-12 hours.

01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)

Molecular Data

Type
Melanocortin receptor agonist
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Sexual Health
Hypoactive Sexual Desire Disorder (HSDD) most effective

FDA-approved for treatment of HSDD in premenopausal women.

Erectile Dysfunction effective

Effective in men including PDE5 inhibitor-resistant cases via CNS pathways.

Female Sexual Arousal Disorder effective

Enhances sexual arousal and desire in women.

Quality of Life
Sexual Distress Reduction effective

Reduces distress related to low sexual desire.

Sexual Satisfaction effective

Enhanced satisfaction reported in clinical trials.

Dosing Protocols

Subcutaneous injection is the FDA-approved route. Administered 45-60 minutes before anticipated sexual activity.

GoalDoseFrequencyRoute
Female HSDD (FDA-approved)1.75mgAs needed, max 1 dose/24hrSubQ
Male Erectile Dysfunction1-2mgAs needed, 45-60min before activitySubQ
Female Arousal Disorder0.75-1.25mgAs needed, max 1 dose/24hrSubQ
Low Starting Dose0.5mgTest dose for tolerance assessmentSubQ

Reconstitution Instructions

Materials Needed:
  • PT-141 lyophilized powder vial
  • Bacteriostatic water (1-2mL)
  • Insulin syringe (29-31 gauge)
  • Alcohol swabs
  • Sterile mixing syringe
  1. 1 Allow vial to reach room temperature (15-20 minutes)
  2. 2 Clean vial tops with alcohol swabs
  3. 3 Draw 1-2mL bacteriostatic water
  4. 4 Inject BAC water slowly down vial side
  5. 5 Gently swirl until fully dissolved (do not shake)
  6. 6 Solution should appear clear and colorless
  7. 7 Store reconstituted solution refrigerated
  8. 8 Use within 30 days of reconstitution

Interactions

~
Sildenafil/Tadalafil
PT-141 works centrally; PDE5 inhibitors work peripherally - monitor for additive BP effects.
monitor
~
Melanotan II
Both are melanocortin agonists; combining risks excessive activation and side effects.
monitor
~
Blood Pressure Medications
PT-141 can transiently lower blood pressure - monitor closely.
monitor
~
Alcohol
Both lower BP and cause flushing - limit intake to avoid excessive hypotension.
monitor
!
Nitrates
Risk of severe hypotension - contraindicated with heart condition medications.
avoid
+
BPC-157
Different mechanisms; no known interactions.
compatible
++
Testosterone
May work synergistically for sexual dysfunction through different pathways.
synergistic
~
Kisspeptin
Different pathways (melanocortin vs GnRH) - no receptor overlap but monitor BP effects.
monitor

What to Expect

0-30 minutes
Mild nausea or facial flushing possible
45-90 minutes
Onset of effects - increased arousal and desire
2-4 hours
Peak effects - enhanced sexual response
6-12 hours
Gradual diminishment of effects

Side Effects & Safety

Common Side Effects

  • Nausea (40%)
  • Flushing (20%)
  • Headache (11%)
  • Injection site reactions

Stop Signs - Discontinue if:

  • Severe or persistent nausea/vomiting
  • Significant blood pressure drop or dizziness
  • Chest pain or irregular heartbeat
  • Severe headache or vision changes
  • Prolonged erection exceeding 4 hours

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Use of nitrate medications
  • Pregnancy or breastfeeding

Quality Checklist

Good Signs

  • FDA-approved pharmaceutical grade (Vyleesi) from licensed pharmacy
  • White crystalline powder (pure PT-141)
  • Clear solution when reconstituted
  • Proper labeling with concentration and purity

Warning Signs

  • Compounded versions - ensure pharmacy is licensed and follows USP standards

Bad Signs

  • Colored or oily appearance indicating impurities or degradation
  • Cloudy solution after reconstitution
  • Unknown source without quality documentation

References

  • Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)
    Kingsberg SA, Clayton AH, Portman D, et al.
    Obstetrics & Gynecology (2019)

    Two identical phase 3, randomized, double-blind, placebo-controlled trials (NCT02333071 and NCT02338960). Bremelanotide 1.75mg SubQ significantly improved sexual desire and reduced related distress in premenopausal women with HSDD.

  • Double-Blind, Placebo-Controlled Evaluation of Intranasal PT-141 in Healthy Males and Patients with Erectile Dysfunction
    Diamond LE, Earle DC, Rosen RC, et al.
    Urology (2004)

    Intranasal PT-141 produced dose-dependent increase in erectile activity at doses >7mg, with onset in ~30 minutes. Safe and well-tolerated in both healthy men and ED patients.

  • The Neurobiology of Bremelanotide for the Treatment of HSDD in Premenopausal Women
    Clayton AH, Kingsberg SA, Goldstein I, et al.
    CNS Spectrums (2021)

    Bremelanotide activates MC4R in the medial preoptic area of the hypothalamus, increasing dopamine release. CNS mechanism of action independent of peripheral vascular effects.

  • Salvage of Sildenafil Failures with Bremelanotide: A Randomized, Double-Blind, Placebo-Controlled Study
    Safarinejad MR
    Journal of Urology (2008)

    342 men with ED unresponsive to sildenafil randomized to 10mg bremelanotide intranasal spray vs placebo. Demonstrated effectiveness in PDE5 inhibitor-resistant cases.

Related Peptides

BPC-157 compatible

Different mechanisms; no known interactions.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.